Exendin 9-39
Exendin 9-39 is a biological therapy with 21 clinical trials. Currently 2 active trials ongoing. Historical success rate of 82.4%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
4
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
82.4%
14 of 17 finished
17.6%
3 ended early
2
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
Regulation of Insulin Secretion by the GLP-1 Receptor
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
Clinical Trials (21)
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
Regulation of Insulin Secretion by the GLP-1 Receptor
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
Cardiovascular Effects of GLP-1 Receptor Activation
Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
Gastrectomy, Eating Behaviour and GLP-1
Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
Effect of DPP4 Inhibition on Growth Hormone Secretion
Glucagon Like Peptide-1 in Remote Ischemic Conditioning
Incretin Regulation of Insulin Secretion in Monogenic Diabetes
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 21